堃博医疗-B(02216)：BroncTarget®肺部靶向去神经射频消融系统进入创新医疗器械特别审查程序_老虎社区_美港股上老虎

堃博医疗-B(02216)：BroncTarget®肺部靶向去神经射频消融系统进入创新医疗器械特别审查程序

智通财经01-12

智通财经APP讯，堃博医疗-B(02216)发布公告，旗下BroncTarget®肺部靶向去神经射频消融系统(以下简称“BroncTarget®系统”)正式进入中国国家药品监督管理局(“ 国家药监局”)的创新医疗器械特别审查程序(国家药监局公示文件中披露产品名为：“肺部射频消融系统”)，标志着该产品在核心技术原创性、临床价值显著性等方面获得国家药监部门的认可。肺部靶向去神经射频消融(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2602517496?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-12 20:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602517496","market":"us","top_or_hot":-1,"title":"堃博医疗-B(02216)：BroncTarget®肺部靶向去神经射频消融系统进入创新医疗器械特别审查程序","media":"智通财经","content":"<div>\n<p>智通财经APP讯，堃博医疗-B(02216)发布公告，旗下BroncTarget®肺部靶向去神经射频消融系统(以下简称“BroncTarget®系统”)正式进入中国国家药品监督管理局(“ 国家药监局”)的创新医疗器械特别审查程序(国家药监局公示文件中披露产品名为：“肺部射频消融系统”)，标志着该产品在核心技术原创性、临床价值显著性等方面获得国家药监部门的认可。肺部靶向去神经射频消融(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1391860.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>堃博医疗-B(02216)：BroncTarget®肺部靶向去神经射频消融系统进入创新医疗器械特别审查程序</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n堃博医疗-B(02216)：BroncTarget®肺部靶向去神经射频消融系统进入创新医疗器械特别审查程序\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-12 20:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1391860.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，堃博医疗-B(02216)发布公告，旗下BroncTarget®肺部靶向去神经射频消融系统(以下简称“BroncTarget®系统”)正式进入中国国家药品监督管理局(“ 国家药监局”)的创新医疗器械特别审查程序(国家药监局公示文件中披露产品名为：“肺部射频消融系统”)，标志着该产品在核心技术原创性、临床价值显著性等方面获得国家药监部门的认可。肺部靶向去神经射频消融(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1391860.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1391860.html","article_id":"2602517496","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602517496","pubTimestamp":1768222714,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，堃博医疗-B 发布公告，旗下BroncTarget肺部靶向去神经射频消融系统正式进入中国国家药品监督管理局的创新医疗器械特别审查程序，标志着该产品在核心技术原创性、临床价值显著性等方面获得国家药监部门的认可。目前，BroncTarget系统的确证性临床试验正在有序开展中，全国28家医院正同步推进受试者招募。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159883":"医疗器械","BK1583":"高瓴概念","02216":"堃博医疗-B","BK1100":"医疗保健设备","09996":"沛嘉医疗-B","BK1222":"医疗保健用品","BK1574":"生物医药B类股","09997":"康基医疗"},"translate_title":"BroncTarget-B (02216): BroncTarget ® Lung Targeted Denervation Radiofrequency Ablation System Enters Special Review Procedure for Innovative Medical Devices","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159883":1.5,"02216":1.5,"09997":1.5,"09996":1.5},"content_text":"智通财经APP讯，堃博医疗-B(02216)发布公告，旗下BroncTarget®肺部靶向去神经射频消融系统(以下简称“BroncTarget®系统”)正式进入中国国家药品监督管理局(“ 国家药监局”)的创新医疗器械特别审查程序(国家药监局公示文件中披露产品名为：“肺部射频消融系统”)，标志着该产品在核心技术原创性、临床价值显著性等方面获得国家药监部门的认可。肺部靶向去神经射频消融(Targeted Lung Denervation，TLD)是一项针对中重度慢性阻塞性肺疾病(慢阻肺，Chronic Obstructive Pulmonary Disease，COPD)的 突破性介入技术。它通过支气管镜将射频能量精准送达神经靶点，旨在从源头上抑制气道异常收缩与黏液高分泌，从而改善咳嗽、咯痰、呼吸困难等症状。该技术与常规药物治疗协同互补的“介入+药物”综合管理方案，尤其为经常规药物治疗后症状仍控制不佳的患者提供了全新的选择方向。BroncTarget®系统创新地采用了环状多电极、可调节圈口、差异化输出射频能量、实时监测调控温度和阻抗、冷盐水智能灌注等设计，保证了射频消融效率和安全性。目前，BroncTarget®系统的确证性临床试验正在有序开展中，全国28家医院正同步推进受试者招募。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}